98 results on '"Shah, Mithun Vinod"'
Search Results
2. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
3. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
4. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
5. The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
6. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy
7. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
8. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
9. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
10. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
11. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
12. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
13. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms
14. Autoimmune manifestations in STAG2-mutated myeloid neoplasms
15. Comparison between GATA2 and DDX41-mutated myeloid neoplasms
16. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
17. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms
18. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
19. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
20. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
21. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
22. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
23. Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.
24. Characteristics and prognosis of mutated STAG2 myeloid neoplasms.
25. Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
26. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
27. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
28. A population‐based study of acute panmyelosis with myelofibrosis in the United States: 2004–2015
29. Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms
30. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval
31. A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series
32. A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004 to 2015.
33. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.
34. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
35. Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis
36. Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia
37. A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015
38. Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias
39. Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia
40. The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis
41. Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients
42. Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
43. Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval
44. A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015
45. Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
46. Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study
47. Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy
48. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
49. Intensive chemotherapy in patients with high grade myelodysplastic syndromes (MDS): A systematic review and meta-analysis.
50. A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.